Skip to main content
Top
Published in:

Open Access 23-10-2024 | Ofatumumab | BRIEF REPORT

COVID-19 Vaccination Response in Patients with Multiple Sclerosis Treated with Ofatumumab in the United States: A Medical Record Review

Authors: Rahul H. Dave, Heidi Crayton, Augusto Miravalle, Ming-Hui Tai, Kerri Wyse, Katherine Houghton, Abby Hitchens, Regina Berkovich

Published in: Neurology and Therapy | Issue 6/2024

Login to get access

Abstract

Introduction

Real-world data are required to provide a greater understanding of the impact of ofatumumab on the ability to mount an effective immune response following the receipt of approved COVID-19 vaccinations. This retrospective real-world analysis aimed to describe the humoral immune response to COVID-19 vaccination during ofatumumab treatment in patients with multiple sclerosis (MS).

Methods

Data from patients with MS treated with ofatumumab who were fully vaccinated against COVID-19 infection were abstracted from medical charts at four clinical sites in the USA. Patient characteristics and humoral response were summarized descriptively. Differences in humoral response were documented on the basis of vaccination status during ofatumumab treatment (i.e., after full vaccination and after booster vaccination) and prior disease-modifying treatment (DMT) exposure (i.e., DMT naïve, prior anti-CD20/sphingosine 1-phosphate [S1P] therapy, prior non-anti-CD20/S1P therapy). The sample size precluded formal statistical analysis.

Results

Thirty-eight patients were included. The mean (standard deviation) duration of ofatumumab treatment upon data collection was 20.4 (4.6) months (treatment ongoing for 35 [92%] patients). Definitive humoral response after full vaccination was documented for 34 patients, of whom 20 (60%) were seropositive. Definitive humoral response after booster vaccination was documented among five patients, of whom three (60%) were seropositive. Among patients who were DMT naïve prior to ofatumumab (n = 15), 73% were seropositive; among patients exposed to prior anti-CD20/S1P therapy (n = 14), 33% were seropositive; and among patients exposed to prior non-anti-CD20/S1P therapy (n = 9), 56% were seropositive. Patients naïve to DMT had been living with an MS diagnosis for a shorter duration than those experienced with DMTs.

Conclusion

Patients with MS receiving ongoing treatment with ofatumumab can mount a positive humoral response to a COVID-19 vaccination. Prior treatment with anti-CD20 or S1P DMTs may be a risk factor for lower humoral response.
Literature
1.
go back to reference Cross AH, Delgado S, Habek M, et al. Characteristics and outcome of COVID-19 in patients with relapsing multiple sclerosis receiving ofatumumab (4123). Neurology. 2021;96:4123.CrossRef Cross AH, Delgado S, Habek M, et al. Characteristics and outcome of COVID-19 in patients with relapsing multiple sclerosis receiving ofatumumab (4123). Neurology. 2021;96:4123.CrossRef
2.
go back to reference Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369(6508):eabc8511.CrossRefPubMedPubMedCentral Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369(6508):eabc8511.CrossRefPubMedPubMedCentral
3.
go back to reference König M, Lorentzen ÅR, Torgauten HM, et al. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. J Neurol Neurosurg Psychiatry. 2023;94(1):19–22.CrossRefPubMed König M, Lorentzen ÅR, Torgauten HM, et al. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. J Neurol Neurosurg Psychiatry. 2023;94(1):19–22.CrossRefPubMed
4.
go back to reference Simon D, Tascilar K, Fagni F, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2021;80(10):1312–6.CrossRefPubMed Simon D, Tascilar K, Fagni F, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2021;80(10):1312–6.CrossRefPubMed
5.
go back to reference Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012836.CrossRefPubMedPubMedCentral Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012836.CrossRefPubMedPubMedCentral
6.
go back to reference Sabatino JJ Jr, Mittl K, Rowles W, et al. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators. Mult Scler Relat Disord. 2023;70:104484.CrossRefPubMed Sabatino JJ Jr, Mittl K, Rowles W, et al. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators. Mult Scler Relat Disord. 2023;70:104484.CrossRefPubMed
7.
go back to reference Capone F, Lucchini M, Ferraro E, et al. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics. 2022;19(1):325–33.CrossRefPubMed Capone F, Lucchini M, Ferraro E, et al. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics. 2022;19(1):325–33.CrossRefPubMed
8.
go back to reference Januel E, Hajage D, Labauge P, et al. Association between anti-CD20 therapies and COVID-19 severity among patients with relapsing-remitting and progressive multiple sclerosis. JAMA Netw Open. 2023;6(6):e2319766.CrossRefPubMedPubMedCentral Januel E, Hajage D, Labauge P, et al. Association between anti-CD20 therapies and COVID-19 severity among patients with relapsing-remitting and progressive multiple sclerosis. JAMA Netw Open. 2023;6(6):e2319766.CrossRefPubMedPubMedCentral
9.
go back to reference Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97:e1870–85.CrossRefPubMedPubMedCentral Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97:e1870–85.CrossRefPubMedPubMedCentral
10.
go back to reference Holroyd KB, Healy BC, Conway S, et al. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: immune profiles and clinical outcomes. Mult Scler Relat Disord. 2022;67:104079.CrossRefPubMedPubMedCentral Holroyd KB, Healy BC, Conway S, et al. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: immune profiles and clinical outcomes. Mult Scler Relat Disord. 2022;67:104079.CrossRefPubMedPubMedCentral
11.
go back to reference Wu X, Wang L, Shen L, Tang K. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: a meta-analysis. EBioMedicine. 2022;81:104102.CrossRefPubMedPubMedCentral Wu X, Wang L, Shen L, Tang K. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: a meta-analysis. EBioMedicine. 2022;81:104102.CrossRefPubMedPubMedCentral
12.
go back to reference Novak F, Nilsson AC, Nielsen C, et al. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis. Mult Scler Relat Disord. 2021;56:103251.CrossRefPubMedPubMedCentral Novak F, Nilsson AC, Nielsen C, et al. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis. Mult Scler Relat Disord. 2021;56:103251.CrossRefPubMedPubMedCentral
13.
go back to reference Tallantyre EC, Vickaryous N, Anderson V, et al. COVID-19 vaccine response in people with multiple sclerosis. Ann Neurol. 2022;91(1):89–100.CrossRefPubMed Tallantyre EC, Vickaryous N, Anderson V, et al. COVID-19 vaccine response in people with multiple sclerosis. Ann Neurol. 2022;91(1):89–100.CrossRefPubMed
14.
go back to reference Bar-Or A, Aburashed R, Chinea AR, et al. Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab. Mult Scler Relat Disord. 2023;79:104967.CrossRefPubMed Bar-Or A, Aburashed R, Chinea AR, et al. Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab. Mult Scler Relat Disord. 2023;79:104967.CrossRefPubMed
15.
go back to reference Bar-Or A, De Seze J, Correale J, et al. Effect of ofatumumab on serum immunoglobulin levels and infection risk in relapsing multiple sclerosis (RMS) patients from the phase 3 ASCLEPIOS I and II trials (1300). Neurology. 2021;96:1300.CrossRef Bar-Or A, De Seze J, Correale J, et al. Effect of ofatumumab on serum immunoglobulin levels and infection risk in relapsing multiple sclerosis (RMS) patients from the phase 3 ASCLEPIOS I and II trials (1300). Neurology. 2021;96:1300.CrossRef
16.
go back to reference Tallantyre EC, Whittam DH, Jolles S, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018;265:1115–22.CrossRefPubMedPubMedCentral Tallantyre EC, Whittam DH, Jolles S, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018;265:1115–22.CrossRefPubMedPubMedCentral
17.
go back to reference Cohen J, Hauser S, Cross A, et al. Five-year safety of ofatumumab in people living with relapsing multiple sclerosis. Neurology. 2023;100:2942.CrossRef Cohen J, Hauser S, Cross A, et al. Five-year safety of ofatumumab in people living with relapsing multiple sclerosis. Neurology. 2023;100:2942.CrossRef
Metadata
Title
COVID-19 Vaccination Response in Patients with Multiple Sclerosis Treated with Ofatumumab in the United States: A Medical Record Review
Authors
Rahul H. Dave
Heidi Crayton
Augusto Miravalle
Ming-Hui Tai
Kerri Wyse
Katherine Houghton
Abby Hitchens
Regina Berkovich
Publication date
23-10-2024
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 6/2024
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-024-00671-0

Other articles of this Issue 6/2024

Neurology and Therapy 6/2024 Go to the issue

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more